Aquestive Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-83.8M | $-44.1M | $-7.9M | $-54.4M | $-70.5M | $-55.8M | $-66.2M | $-61.4M |
| Depreciation & Amortization | $548.0K | $718.0K | $1.3M | $2.4M | $3.0M | $3.4M | $2.9M | $3.2M |
| Depreciation | $548.0K | $640.0K | $1.2M | $2.3M | $2.9M | $3.4M | $2.9M | $3.2M |
| Amortization | $0 | $78.0K | $157.0K | $116.0K | $51.0K | $51.0K | $50.0K | $50.0K |
| Stock-Based Compensation | $7.6M | $7.1M | $2.7M | $4.4M | $6.8M | $6.6M | $7.1M | $29.9M |
| Net Cash from Operating Activities | $-52.4M | $-35.8M | $-6.4M | $-9.8M | $-33.0M | $-45.5M | $-60.2M | $-13.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $562.0K | $159.0K | $995.0K | $1.0M | $913.0K | $517.0K | $663.0K | $1.8M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-562.0K | $-159.0K | $-995.0K | $-2.5M | $-913.0K | $-517.0K | $-663.0K | $-1.8M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $102.6M | $83.6M | $4.0M | $11.6M | $30.1M | $28.5M | $49.6M | $58.0M |
| Net Change in Cash | $49.6M | $47.7M | $-3.4M | $-751.0K | $-3.8M | $-17.5M | — | $43.2M |
| Free Cash Flow | $-53.0M | $-35.9M | $-7.4M | $-10.8M | $-33.9M | $-46.0M | $-60.9M | $-14.8M |